January 11, 2022
Yuliya Pylayeva-Gupta, PhD, is a recipient of The Mark Foundation for Cancer Research Emerging Leader Award. The funding will support her research focused on reprogramming B cell fate and function in cancer.
October 6, 2021
Researchers from UNC Lineberger and colleagues report pairing a newly developed gel with immunotherapy that was delivered to post-surgical lab models with glioblastoma improved the immunotherapy’s effectiveness.
September 23, 2021
Hongwei Du, PhD, Gianpietro Dotti, MD, and colleagues developed a new therapeutic approach that has shown successful results in lab models.
September 10, 2021
Josh Zeidner, MD, Jon Serody, MD, and colleagues report clinical trial outcomes that benefited patients with resistant or relapsed acute myeloid leukemia.
August 30, 2021
Tracy Rose, MD, MPH, Matthew Milowsky, MD, and colleagues report that the regimen reduced the invasiveness of the cancer in 56% of patients in a phase II clinical trial.
July 27, 2021
Led by William Kim, MD, and colleagues, this research has important implications for patients who have not been offered immunotherapy because of their genetic profiles.
April 23, 2021
Barbara Savoldo, MD, PhD, and Gianpietro Dotti, MD, have established a fund to develop a CAR-T therapy for glioblastoma in honor of Savoldo's sister, Sonia.
March 4, 2021
As part of a study led by Matthew Foster, MD, the advance was seen in a patient enrolled in a clinical trial using CAR-T to treat refractory acute B-cell leukemia.
January 25, 2021
The European Medicines Agency granted priority medicines designation to Tessa Therapeutics’ CD30 targeted CAR-T therapy for patients with relapsed or refractory Hodgkin lymphoma.
November 17, 2020
Immunotherapies effective against lung cancer and melanoma may also work against cutaneous angiosarcoma, a rare and highly aggressive skin tumor.
